Should I buy or sell Inovio Pharmaceuticals stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" INO shares. View INO analyst ratings or view top-rated stocks .

What is Inovio Pharmaceuticals' stock price target for 2024?

3 brokers have issued twelve-month price targets for Inovio Pharmaceuticals' stock. Their INO share price targets range from $48.00 to $144.00. On average, they predict the company's stock price to reach $96.00 in the next year. This suggests a possible upside of 891.7% from the stock's current price. View analysts price targets for INO or view top-rated stocks among Wall Street analysts .

How have INO shares performed in 2024?

Inovio Pharmaceuticals' stock was trading at $73.44 on January 1st, 2024. Since then, INO shares have decreased by 86.8% and is now trading at $9.68. View the best growth stocks for 2024 here .

When is Inovio Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our INO earnings forecast .

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($18.72) earnings per share for the quarter, topping analysts' consensus estimates of ($20.16) by $1.44. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 79.86% and a negative net margin of 16,238.91%. During the same period in the prior year, the firm posted ($66.24) EPS.

What ETF holds Inovio Pharmaceuticals' stock?

Invesco Nasdaq Future Gen 200 ETF holds 4,633 shares of INO stock, representing 0.68% of its portfolio.

When did Inovio Pharmaceuticals' stock split?

Inovio Pharmaceuticals's stock reverse split on the morning of Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?

12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com . J. Joseph Kim has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Inovio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX) , Moderna (MRNA) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Tesla (TSLA) , Pfizer (PFE) , Micron Technology (MU) , Sorrento Therapeutics (SRNE) and Vaxart (VXRT) .

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Green Alpha Advisors LLC (0.16%). Insiders that own company stock include David B Weiner, David B Weiner , Jacqueline Elizabeth Shea , Laurent Humeau , Lota S Zoth , Peter Kies and Simon X Benito . View institutional ownership trends .

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

→ This company has increased its dividend every year for 54 years (From DTI) (Ad)

Free INO Stock Alerts

$9.68

-0.52 (-5.10%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.55
▼
$10.20
50-Day Range: $6.53
▼
$13.88
52-Week Range: $3.89
▼
$14.75

Volume: 352,885 shs
Average Volume: 528,438 shs
Market Capitalization: $226.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $96.00

Get Inovio Pharmaceuticals alerts:

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 891.7% Upside
$96.00 Price Target
Short Interest: Bearish
9.14% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.74
Upright™ Environmental Score
News Sentiment: 0.00
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($4.09) to ($3.09) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.92 out of 5 stars

Medical Sector

375th out of 911 stocks

Surgical & Medical Instruments Industry

43rd out of 97 stocks

3.3

Analyst's Opinion

Consensus Rating
Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.14% of the float of Inovio Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Inovio Pharmaceuticals has recently increased by 1.94%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Inovio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Inovio Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Inovio Pharmaceuticals has received a 73.19% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for cancer", "Clinical research services for infectious diseases", and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Inovio Pharmaceuticals is -0.74.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 3 news articles for Inovio Pharmaceuticals this week, compared to 2 articles on an average week.
Search Interest
Only 15 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.90% of the stock of Inovio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.09) to ($3.09) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inovio Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inovio Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inovio Pharmaceuticals has a P/B Ratio of 1.88. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Don’t expose yourself to stocks during the week

The S&P 500 just crossed below the 200 day moving average… The Nasdaq is bleeding out… Are we headed for a recession?! If you’ve been in the stock market the last few months, it hasn’t been fun… But what if I told you there was a way to target “BONUS” income just by doing a unique type of trade over the weekend? When the markets are closed. And volatility is minimal.

Click here and I’ll give you all the details.

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

INO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INO Stock News Headlines

April 16, 2024 | bizjournals.com

Inovio set to raise $36M following 'strategic refocus'

April 15, 2024 | markets.businessinsider.com

Inovio Announces Pricing Of About $36 Mln Offering Of Stock And Pre-Funded Warrants; Stock Drops

April 19, 2024 | DTI (Ad)

Here’s how to start a “Weekend Side Hustle” from your sofa

Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand.

April 15, 2024 | prnewswire.com

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

April 2, 2024 | msn.com

INOVIO's Leadership to Spotlight Innovative Disease-Fighting Technologies at Citizens JMP Novel Therapeutics Forum

March 29, 2024 | finance.yahoo.com

Global Human Vaccines Market (2023-2028)

March 26, 2024 | prnewswire.com

INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine

March 11, 2024 | benzinga.com

Peering Into Inovio Pharmaceuticals's Recent Short Interest

April 19, 2024 | DTI (Ad)

Here’s how to start a “Weekend Side Hustle” from your sofa

March 10, 2024 | ca.finance.yahoo.com

INO Mar 2024 6.500 call

March 7, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals: Hold Rating with Promising Pipeline Despite Financial Losses

March 7, 2024 | finance.yahoo.com

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q4 2023 Earnings Call Transcript

March 7, 2024 | finance.yahoo.com

Q4 2023 Inovio Pharmaceuticals Inc Earnings Call

March 7, 2024 | fool.com

Inovio Pharmaceuticals (INO) Q4 2023 Earnings Call Transcript

March 6, 2024 | benzinga.com

Recap: Inovio Pharmaceuticals Q4 Earnings

March 6, 2024 | benzinga.com

Preview: Inovio Pharmaceuticals's Earnings

March 6, 2024 | markets.businessinsider.com

Inovio Pharmaceuticals Inc. Q4 Loss Narrows

March 6, 2024 | finance.yahoo.com

Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

March 6, 2024 | finance.yahoo.com

INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

February 24, 2024 | msn.com

Inovio Pharmaceuticals (INO) Price Target Increased by 2590.47% to 19.21

February 21, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know

February 21, 2024 | finance.yahoo.com

Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know

February 21, 2024 | finance.yahoo.com

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

February 21, 2024 | prnewswire.com

INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024

February 5, 2024 | msn.com

Penn’s BRCA cancer vaccine trial aims to prevent the disease in healthy people

February 2, 2024 | finanznachrichten.de

INOVIO Pharmaceuticals, Inc.: INOVIO Reports Inducement Grant Under Inducement Plan

January 30, 2024 | finance.yahoo.com

How Much Upside is Left in Inovio (INO)? Wall Street Analysts Think 223.72%

See More Headlines

Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/09/2023
Today: 4/19/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:INO
CUSIP: N/A
CIK: 1055726
Web: www.inovio.com
Phone: (267) 440-4200
Fax: 267-440-4242
Employees: 122
Year Founded: 1979

Price Target and Rating

Average Stock Price Target: $96.00
High Stock Price Target: $144.00
Low Stock Price Target: $48.00
Potential Upside/Downside: +891.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.5630)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-135,120,000.00
Net Margins: -16,238.91%
Pretax Margin: -16,240.02%
Return on Equity: -79.86%
Return on Assets: -57.71%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.60
Quick Ratio: 3.60

Sales & Book Value

Annual Sales: $830,000.00
Price / Sales: 272.56
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.16 per share
Price / Book: 1.88

Miscellaneous

Outstanding Shares: 23,370,000
Free Float: 22,926,000
Market Cap: $226.22 million
Optionable: Optionable
Beta: 1.11

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Jacqueline E. Shea Ph.D. (Age 58)
CEO, President & Director
Comp: $1.08M
Mr. Peter D. Kies (Age 61)
Chief Financial Officer
Comp: $688.72k
Dr. Laurent M. Humeau Ph.D. (Age 57)
Chief Scientific Officer
Comp: $673.59k
Thomas Hong
Manager of Investor Relations
Mr. Robert L. Crotty J.D. (Age 50)
General Counsel & Chief Compliance Officer
Mr. E. J. Brandreth MBA
Senior Vice President of Quality Assurance
Dr. Jeffrey Skolnik
Senior Vice President of Clinical Development
Mr. Robert J. Juba Jr.
Senior Vice President of Biological Manufacturing & Clinical Supply Management
Mr. Stephen Kemmerrer M.B.A.
P.E., Senior Vice President of Engineering Development
Mr. Shawn D. Bridy M.A.
M.B.A., Senior Vice President of Business Development

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

INO Stock Analysis - Frequently Asked Questions

Should I buy or sell Inovio Pharmaceuticals stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inovio Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" INO shares.
View INO analyst ratings or view top-rated stocks.
What is Inovio Pharmaceuticals' stock price target for 2024?: 3 brokers have issued twelve-month price targets for Inovio Pharmaceuticals' stock. Their INO share price targets range from $48.00 to $144.00. On average, they predict the company's stock price to reach $96.00 in the next year. This suggests a possible upside of 891.7% from the stock's current price.
View analysts price targets for INO or view top-rated stocks among Wall Street analysts.
How have INO shares performed in 2024?: Inovio Pharmaceuticals' stock was trading at $73.44 on January 1st, 2024. Since then, INO shares have decreased by 86.8% and is now trading at $9.68.
View the best growth stocks for 2024 here.
When is Inovio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our INO earnings forecast.
How were Inovio Pharmaceuticals' earnings last quarter?: Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($18.72) earnings per share for the quarter, topping analysts' consensus estimates of ($20.16) by $1.44. The biopharmaceutical company had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.20 million. Inovio Pharmaceuticals had a negative trailing twelve-month return on equity of 79.86% and a negative net margin of 16,238.91%. During the same period in the prior year, the firm posted ($66.24) EPS.
What ETF holds Inovio Pharmaceuticals' stock?: Invesco Nasdaq Future Gen 200 ETF holds 4,633 shares of INO stock, representing 0.68% of its portfolio.

When did Inovio Pharmaceuticals' stock split?: Inovio Pharmaceuticals's stock reverse split on the morning of Thursday, January 25th 2024. The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What is J. Joseph Kim's approval rating as Inovio Pharmaceuticals' CEO?: 12 employees have rated Inovio Pharmaceuticals Chief Executive Officer J. Joseph Kim on Glassdoor.com. J. Joseph Kim has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Inovio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inovio Pharmaceuticals investors own include Novavax (NVAX), Moderna (MRNA), Gilead Sciences (GILD), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE), Micron Technology (MU), Sorrento Therapeutics (SRNE) and Vaxart (VXRT).
Who are Inovio Pharmaceuticals' major shareholders?: Inovio Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Green Alpha Advisors LLC (0.16%). Insiders that own company stock include David B Weiner, David B Weiner, Jacqueline Elizabeth Shea, Laurent Humeau, Lota S Zoth, Peter Kies and Simon X Benito.
View institutional ownership trends.
How do I buy shares of Inovio Pharmaceuticals?: Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

INO Stock Price History

INO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Institutional Ownership

INO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™